Investor Farooq Abbasi explains $700M bet on whole-body scanning startup Neko Health
Preface Ventures partner discusses why Neko Health’s massive funding reflects growing confidence in preventive body-scan technology.
The latest episode of TechCrunch’s Equity podcast highlighted a $700 million financing round for Neko Health, the health-tech venture founded by Spotify co-founder Daniel Ek. The discussion, hosted by senior venture reporter Dominic-Madori Davis, featured Farooq Abbasi, founder and general partner at Preface Ventures, who sits on Neko Health’s investor side. Abbasi explained why such a large sum is being placed on a company whose core product is a full-body scanner aimed at preventive health care.
Neko Health’s fundraising marks one of the largest single investments in a consumer-health startup to date. The capital is intended to develop hardware and software capable of scanning an entire human body quickly and non-invasively, with the goal of detecting disease before symptoms appear. Abbasi noted that the market opportunity lies in shifting health care from reactive treatment to early detection, a transition that could reduce overall medical costs and improve outcomes. He also pointed to the credibility that Ek’s reputation brings, suggesting that founder pedigree continues to influence investor confidence in emerging health technologies.
The podcast placed Neko Health within a broader wave of companies targeting preventive diagnostics. Midjourney, known for its generative-AI art platform, is reportedly building its own body-scanner prototype, while Function Health has secured a sizable, though undisclosed, funding round to expand its preventive-health platform. Abbasi argued that the convergence of AI, imaging technology, and consumer demand for health insights is creating a fertile environment for multiple entrants. He emphasized that investors are looking for scalable solutions that can integrate with existing health-care systems and generate recurring revenue through subscription or per-scan models.
According to Abbasi, several hurdles must be cleared before whole-body scanning becomes mainstream. Regulatory approval is a primary barrier; devices must demonstrate safety and clinical validity to satisfy agencies such as the FDA. Additionally, data privacy and integration with electronic health records will require robust infrastructure and clear standards. Abbasi suggested that partnerships with hospitals, insurers, and large employers could accelerate adoption by embedding scans into routine wellness programs.
Looking ahead, Abbasi expects the next few years to determine whether the $700 million wager will pay off. He highlighted that founders in this space need to focus on proving clinical utility, achieving cost-effective manufacturing, and building trust with both patients and providers. For investors, the lesson is to monitor not only the technology roadmap but also the evolving regulatory landscape and reimbursement models. As the conversation on the podcast concluded, the success of Neko Health and its peers could reshape how preventive health is delivered, but the path to widespread acceptance remains uncertain.